Indication

Percutaneous coronary intervention adjunct for thrombosis prevention

Percutaneous coronary intervention adjunct for thrombosis prevention describes a therapeutic indication aimed at preventing acute, subacute, and late thrombotic complications in patients undergoing coronary revascularization. Read more about Percutaneous coronary intervention adjunct for thrombosis prevention

51 drugs 38 manufacturers

Advertisement

Drugs that treat it

Common Percutaneous coronary intervention adjunct for thrombosis prevention therapies.

Showing 19–27 of 51 drugs

BIVALIRUDIN

THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
APOTEX CORP

BIVALIRUDIN

THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
Hospira

BIVALIRUDIN

THROMBIN INHIBITORS (NON-HEPARINOID)·THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION·+2
FRESENIUS KABI

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR·ACUTE CORONARY SYNDROME·+1
ACCORD HEALTHCA

KENGREAL (cangrelor tetrasodium)

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW·PERCUTANEOUS CORONARY INTERVENTION ADJUNCT FOR THROMBOSIS PREVENTION
CHIESI USA, INC

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR·ACUTE CORONARY SYNDROME·+1
SAGENT PHARMACE

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR·ACUTE CORONARY SYNDROME·+1
MYLAN INSTITUTI
Filter & compare in the drug finder →Opens the drug finder with Percutaneous coronary intervention adjunct for thrombosis prevention preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Percutaneous coronary intervention adjunct for thrombosis prevention.

Percutaneous coronary intervention adjunct for thrombosis prevention describes a therapeutic indication aimed at preventing acute, subacute, and late thrombotic complications in patients undergoing coronary revascularization.

Mechanical disruption of atherosclerotic plaques, vascular endothelial denudation, and the introduction of endovascular hardware—such as balloon catheters and intracoronary stents—stimulate platelet activation, adhesion, and cascade thrombin generation within the coronary arterial vasculature.

Without pharmacological inhibition, this prothrombotic state can lead to abrupt periprocedural vessel closure, stent thrombosis, distal microvascular embolization, and recurrent myocardial infarction.

Adjunctive antithrombotic regimens address this risk by suppressing platelet aggregation and the coagulation cascade during and following the procedure, thereby maintaining coronary vessel patency and reducing ischemic cardiovascular events.

Personalize your experience

Follow Percutaneous coronary intervention adjunct for thrombosis prevention and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it